COMMUNIQUÉS West-GlobeNewswire

Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market

07/01/2019 - 07:01

PRESS RELEASE 7 January 2019, 07:00 CET Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market Mechelen, Belgium, 7 January 2019 - Biocartis Group NV (the 'Company' or 'Biocartis [...]

Addex Trading Update: Completes 2018 with Strong Cash Position

07/01/2019 - 07:00

Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed the year 2018 with [...]

Innate Pharma : Upcoming investor conferences

07/01/2019 - 07:00

UPCOMING INVESTOR CONFERENCES Marseille, France, January 7, 2019, 7:00 AM CET Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor [...]

Innate Pharma : Prochains rendez-vous investisseurs

07/01/2019 - 07:00

PROCHAINS RENDEZ-VOUS INVESTISSEURS Marseille, le 7 janvier 2019, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce aujourd’hui qu’elle sera présente aux événements investisseurs suivants : LifeSci [...]

Xenon Pharmaceuticals Outlines 2019 Key Milestones

07/01/2019 - 03:00

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]

Adverum Biotechnologies Provides 2019 Outlook

07/01/2019 - 02:00

Advancing Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 Clinical Trial MENLO PARK, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company [...]

Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018

07/01/2019 - 01:00

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that its Board of [...]

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

06/01/2019 - 22:02

Mechelen, Belgium; 6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program [...]

Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019

06/01/2019 - 17:38

-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700 for the fourth [...]

Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference

06/01/2019 - 14:00

EMERYVILLE, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, [...]

Executive Women In Bio Releases First Annual Directory of Boardroom Ready Executive Profiles

05/01/2019 - 14:00

Applications for the 2019 Boardroom Ready program now open NEW YORK, Jan. 05, 2019 (GLOBE NEWSWIRE) -- Executive Women In Bio (EWIB), a committee comprised of senior leaders in biopharma and the life sciences operating [...]

CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones

05/01/2019 - 00:15

In a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical development to initiating [...]

ChemioCare Initiates Development Program in Pediatric CINV

04/01/2019 - 23:52

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult Ondansetron 5-day adhesive [...]

Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer

04/01/2019 - 23:00

Expects Enrollment of Phase 1 Trial to Begin in the First Quarter of 2019 NEW HAVEN, Conn., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on [...]

Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions

04/01/2019 - 22:53

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. , a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, [...]

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/01/2019 - 22:30

BURLINGTON, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. [...]

Amarin Provides Preliminary 2018 Results and 2019 Outlook

04/01/2019 - 22:15

U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa® Cardiovascular Outcomes Study Presented in November 2018 Unaudited Full-Year 2018 Net Total Revenue [...]

Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference

04/01/2019 - 22:05

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]

Fibrocor and Galapagos sign partnership in fibrosis

04/01/2019 - 22:02

Mechelen, Belgium; 4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel [...]